Pump and Sensor Data Interpretation. Irl B. Hirsch, MD University of Washington School of Medicine

Similar documents
Diabetes Technology in Irl B. Hirsch, MD University of Washington School of Medicine Seattle, WA

Applications of Technologies to Your Patient. Irl B. Hirsch, MD Professor of Medicine University of Washington School of Medicine Seattle, Washington

Using and Interpreting Diabetes Data. Irl B. Hirsch, MD University of Washington

Diabetes Technology for the Endocrinologist, Irl B. Hirsch, MD University of Washington

Technology in Diabetes Management Irl B. Hirsch, MD University of Washington

CGM and Closing The Loop

Incorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA

1. Continuous Glucose Monitoring

Emerging Automated Insulin Delivery Systems

Insulin Pumps and Continuous Glucose Sensors- Embracing Technology. Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education

Diabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018

CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION

Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim

Technology in Diabetes Care: Emerging Level

Making the Most of Continuous Glucose Monitoring

The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes

The Realities of Technology in Type 1 Diabetes

5/18/2010. History of 1,5 Anhydroglucitol (1,5 AG) Glucose Variability & Pattern Management: Way Beyond Logbooks. Normal Renal Glucose Handling

How I use the latest technology to investigate and treat a person with Type 1 Diabetes. Dr Pratik Choudhary

NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP

Update on Diabetes Technology

Glucose Variability & Pattern Management: Way Beyond Logbooks Irl B. Hirsch, M.D. University of Washington, Seattle, WA

Dr Sander Zwart MD, FACP, ECNU Arizona-AACE 2016 Annual Meeting

More Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center

Diabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE

Advances in Diabetes Care Technologies

Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?

When Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida

What is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming

Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical

Real-Time Continuous Glucose Monitoring: From Application to Evaluation

Continuous Glucose Monitoring (CGM)

Updates in Diabetes Technology

Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)

Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections. Aaron Michels MD

PROTOCOL FOR HYBRID CLOSED LOOP TECHNOLOGY

ADVANCES IN DIABETES TECHNOLOGY: A FOCUS ON CONTINUOUS GLUCOSE MONITORING 9:15 10:15 AM

Making Sense of Glucose Monitoring. My Journey with Glucose Monitoring Over the Last 37 Years 8/7/2017

Advances in Diabetes Care Technologies

DIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson

DIABETES & ENDOCRINE DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT

Pumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University

Incorporating CGM Into Clinical Decision

Advances in Diabetes Care Technologies

OBJECTIVES THE PAST INNOVATIVE TECHNOLOGY & DIABETES DIABETES MIS MANAGEMENT IMPROVEMENTS IN DIABETES MANAGEMENT

Report Reference Guide

Advances in Diabetes Technology Part II: Analysis of Diabetes Self Management Devices and Support Tools

CareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes

THERAPY MANAGEMENT SOFTWARE FOR DIABETES

Using the Bolus Wizard Calculator

Today s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures

Report Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1

THERAPY MANAGEMENT SOFTWARE FOR DIABETES

CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION

Continuous Glucose Monitoring (CGM) Dexcom G6 Training for Healthcare Professionals and Patients

Continuous Glucose Monitors for Diabetes Management

Approved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services.

Welcome to CareLink Pro

THE MINIMED 670G SYSTEM SCHOOL NURSE GUIDE

UNDERSTANDING THE BASIC FEATURES AND MANAGEMENT IN THE SCHOOL SETTING CHRISTINE HERTLER RN BSN CDE & MARY MCCARTHY RN CDE

Continuous Glucose Monitoring

Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM

MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps

Glucometers Gastrostomy Tubes Nasogastric Tubes Insulin pumps Continuous Glucose monitoring system Closed Loop Smart phones/tablets

Diabetes Management: Current High Tech Innovations

Corporate Medical Policy

Flash Glucose Monitoring & Implantable Sensors

ssociation of Children s Diabetes Clinicians Clinicians Continuous Glucose Monitoring (CGM) Training for Healthcare Professionals and Patients

Understanding the CareLinkTM Sensor Meter Overview Report: Page 1

Abbott FreeStyle Libre Pro System

Current Glucometers. Junior s s Glucose Log. All have advantages and disadvantages Answer 2

7/18/2017. Everything discussed in this presentation is off-label. (And that s ok.) Dana Lewis Founder, #OpenAPS WARNING: Disclosure to Participants

QUESTION 4. WHAT CLINICAL DATA ARE CURRENTLY AVAILABLE TO SUPPORT EXPANDED CGM COVERAGE BY PAYERS AS PERTAINS TO QUESTIONS 1 AND 3?

Update on Continuous Glucose Monitoring (CGM) Technology in Diabetes. Elena Toschi, MD November 12, 2016

MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps

BASICS OF INSULIN PUMPS. Jennifer Okemah MS RD BCADM CDE CSSD

Paradigm/Guardian CGM Screens. CareLink Online Reports. Make Your Own Jackson Pollack. CGM by Jackson Pollack. How To Read CGM Screens/Reports

MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps

INSPIRED BY GIVE HIM MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs.

THE SHEFFIELD AREA PRESCRIBING GROUP. Position Statement for Prescribing of Freestyle Libre In Type 1 Diabetes. Date: March 2018.

Abbott FreeStyle Libre Pro System

New Therapies for Diabetes Management: Hope or Headache?

Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES

INSPIRED BY GIVE HER MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs.

VIRTUAL PATIENTS DERIVED FROM THE

Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico

Objectives. Glucose Monitoring Today. Tracking Glucose ISO Standards. Continuous Glucose Monitoring & Diabetes Management 3/7/2015

LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA

Clinical News and Innovation in Type 1 Diabetes and Technology. Parth Narendran University Hospitals Birmingham

CGM: Continuous Glucose Monitoring Making Sense of It All AW: ANCO/GEND/1016/0117

Technology for Diabetes: 101 Basic Rules of the Road. Karen Hamon RN, BSN, CDE Stephen Stone MD, FAAP Neil H. White, MD, CDE

DIABETES TECHNOLOGY: ENDLESS CHOICES FOR HEALTHY MANAGEMENT

Understanding the CareLink TM Therapy Management Dashboard Report

Future Direction of Artificial Pancreas. Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida

NEWS BRIEFING Advances in Technology. moderated by: Irl Hirsch, MD University of Washington Medical Center

Interpreting the charts & graphs

INVESTOR DAY JUN 5, 2018 NEW YORK CITY

Usefulness of Ambulatory Glucose Profile (AGP) in Diabetes Care

31 days Wed Nov 15, Fri Dec 15, 2017 N/A. Hypoglycemia. Sensor usage (CGM) Mahlon's glucose data was in the target range about 77% of the day.

Transcription:

Pump and Sensor Data Interpretation Irl B. Hirsch, MD University of Washington School of Medicine

Dualities Research: Medtronic Diabetes Consulting: Abbott Diabetes Care, BD, Bigfoot, Roche

Raise Your Hand If In Your Practice Every patient gets their meter downloaded Every patient gets their pump downloaded Every patient gets their CGM downloaded No patient gets downloaded, but you encourage your patients to download at home If your downloads are uploaded into your EMR

What You Need (Minimal) A program which allows downloading of various meters/pumps/sensors Clinipro (Numedics.com), Glooko/Diasend, Carelink, Tidepool Ideally, many of the native softwares are also available A better solution: immediate upload to the cloud Livongo, Accucheck Aviva Connect, Dexcom Clarity Clarity Given all of the nuances we are appreciating with HbA1c, using TIRs from CGM is becoming a new standard

International Consensus Panel Recommendations Self-evident glucose metrics for patients, clinicians, and researchers 5 thresholds TIR: 70-180 mg/dl (3.9-10.0 mmol/l) TBR: < 70 mg/dl (< 3.9 mmol/l)*; < 54 mg/dl (< 3.0 mmol/l)** TAR: > 180 mg/dl (> 10.0 mmol/l); > 250 mg/dl (> 13.9 mmol/l In addition to (or as opposed to) A1C, we can now compare studies to each other by comparing buckets and patients can now also be compared-not like A1C * alert hypoglycemia; ** severe hypoglycemia; Danne T, et al: Diabetes Care 2017;40:1631-40

Transitioning is Always Difficult For glycemic variability, it is time to transition away from SD and to CV For > 25 years: SD X 3 < mean (for means 120-180 mg/dl) has been our target Consensus: CV (SD/mean) a better metric CV target: 36? 33?

But For a Busy Endocrine Practice, Why Treat the Glucose (and spend time with downloading) and Not Simply the HbA1c, Especially for T2D Not Receiving Insulin? ACP: Most patients with T2D should aim to achieve HbA1c a HbA1c level between 7-8% A1C (%) AG (mg/dl [95% CI]) 5 97 (76-120) 6 126 (100-152) 7 154 (123-185) 8 183 (147-217) 9 212 (170-249) 10 249 (192-282) 11 269 (217-314) 12 298 (240-347) Based on the new ACP Guidelines glucose targets can range from an average of 123 to 217 mg/dl (not including all of the discordant patients we ve discovered)

HbA1c levels for a Given Time in Range (70-180 mg/dl) for an Individual with T1D Measured TIR Estimated HbA1c 95% CI 40% 8.1% 7.1-9.1% 50% 7.7% 6.6-8.7% 60% 7.2% 6.2-8.3% 70% 6.8% 5.8-7.8% 80% 6.4% 5.2-7.4% Beck R: ATTD, Vienna, 2018 8

The Painful Reality: Few Endocrinologists Routinely Look at Downloads Due to The Time Commitment and Overwhelming Data Presentation

ONE Reason Why Downloading Is So Important: Understanding the Mean and Estimated A1C 24 year-old woman, MDI, using Dexcom, 14 years T1D This patient s HbA1c is 8.2%. She has a discordance with her A1C due to iron deficiency anemia

Hematologic conditions Anemia Accelerated erythrocyte turnover Thalassemia Sickle cell disease Reticulocytosis Hemolysis Physiologic States Aging Pregnancy Drugs/Medications Alcohol Opioids Vitamin C Vitamin E Aspirin Erythropoetin Dapsone Ribavirin What Alters A1C Disease States HIV infection Uremia Hyperbilirubinemia Dyslipidemia Cirrhosis Hypothyroidism* Medical Therapies Blood transfusion Hemodialysis In a typical diabetes practice, about 20% of A1C measurements are misleading Miscellaneous Glycation rate Protein turnover Race and ethnicity* Laboratory assay Glycemic Variability Smoking Mechanical heart valves Exogenous testosterone?

CASE 2: 20 y/o T1D, Down Syndrome T1D X 11 years, CSII and CGM. Last SH 5 years ago; HbA1c 7.6%

High basals in the evening do help to cushion dinner but usually result in hypoglycemia if not snacking. Timing of nocturnal basal change is important! Hypoglycemic seizure at 1:30am. Why?

What Happens When This Patient (now 21 years-old) Goes on a 670G? Raise your hand if you have at least 1 patient on a 670g? Raise your hand if you have more than 10 patients on a 670 g? My opinion: for the right patient personality, they clearly improve diabetes control and quality-of-life There are certain patient personalities they don t work well-like everything there are pros and cons and while this is an advancement in our technology, it is a first (but important) step

Case 2a: 15 months later

Case 2a: HCL No sensors! Need more aggressive ICR?

Case 2a: HCL

What I Did Shorter AITr More aggressive ICR

What Are The Goals with Hybrid Closed Loop Pumps? Pivotal trial (N=124, mean age 38 years, A1C 7.4%, 12 weeks no control group): TIR: 72% TBR: 3.3%* TAR: 9.2% A1C: 6.9% Mean glucose: 148 mg/dl* Basal insulin: 46%* * My observations: Difficult to obtain mean glucose less than 140 mg/dl with current HCL systems. Goal TBR is < 4%. Almost everyone who does well needs less basal than bolus insulin (often 40%)

Problems in 2018 With our Technology Daily details on Carelink which allows us to understand if the bolus calculator is working correctly taken away from manual mode in 670g Smart Pens only now becoming available for MDI patients (my prediction: this will be the biggest change to our practices in the next 3 years Solutions: use of other software

Case 3: Included With Infrastructure: Assessing The Data With Other Pump/CGM 38 y/o woman with T1D preparing for pregnancy Uses OmniPod and Libre (Libre started 12/17) BMI 30; on hypocaloric diet to lose weight A1C 11/17= 7.4% Details of boluses, over-rides, temp basals important but views from the sky can also be important

Tidepool Carbs, amount suggested, amount delivered with Libre 1. Increase basal 10p-4a 2. Less aggressive carb ratio with more use of extended boluses with dinner

Opinion: Bolus Calculators Are An Important and Under-Utilized Tool BUT, they are not smart! If the glucose is trending up or down, more or less insulin will be required Estimate Details: Bolus Calculator Est. total 4.5 U Food intake 36 g (meter) BG 210 Food 3 U Correction 2 U IOB 0.5 U

CASE 4: A Common Problem 59 y/o woman with hypoglycemia unawareness T1D since 11 years old No interest to use CSII; A1C rarely below 8% x 20 years 2014-2015: monthly severe hypoglycemia, insurance refused payment for CGM Dec 2015: after much discussion, CGM allowed 25

First CGM Download, January 2016 Mean/SD = 168/70; A1C 7.9% 26

Worked with Patient and Husband Use of share app Focused on frequent looking of data Adjusted both basal and bolus insulin accordingly Upgraded to G5 Most important: learned how to use trend arrows J Endo Soc 2017;1:1445-1460

2 Years Later

FreeStyle Libre All CGM systems have the same general accuracy in the 80-200 mg/dl range Libre has a higher MARD with blood glucose < 70 mg/dl (MARD 24%) (BMJ Open Diabetes Research and Care 2017;5:e000320. doi:10.1136/bmjdrc-2016-000320) Results can read low, meaning insulin-requiring patients may be tempted to treat perceived hypoglycemia when none is actually present The device gives an icon to measure blood glucose to mitigate this problem

Case 5: 64 y/o Lawyer with T2D History of RA and breast cancer, now not on steroids T2D X 10 years, recently moved to Seattle from SF area Receiving glipizide, metformin, and liraglultide When first seen placed Libre Pro on her. HbA1c at the time was 6.0%

March/April, 2017

March/April 2017 Glipizide stopped, blood sugars spiked into high 100s, started empagliflozin, later started Libre 12/17

March, 2018 Measured HbA1c = 6.5%

New Old CGM for MDI Patients Medtronic Guardian Connect: Guardian 3 CGM CASE 6: -55 y/o man trying to determine basal dose using degludec and aspart -He now takes 18 units of degludec with aspart at an ICR of 1/12 and an ISF of 40

DAY 1 2 units aspart I have no idea! Smart pens will make this much easier to understand Hypoglycemia: what s the problemthe degludec or the aspart?

Case 7: AGP from 60 y/o Woman Recently Dx ed with SPS Feb 2016, HbA1c 10.1%; Last A1C 7.3% h

CASE 7: The Answer to the Problem No bolus

Case 7: First week on HCL (2/18)

Case 7: First Week on HCL

What I Want To See In A Download Basic statistics Overall and time specific means/sd SMBG standard: SD X 3 < mean if mean 120-180 CGM: SD X 3 < mean or CV < 33 CSII: Basic insulin stats TDD, % basal, over-ride % for bolus calculator Daily summary to better understand ICR, ISF, basal rates, and if appropriate over-under-rides for trends or anticipated exercise CGM: basic BG stats Overall patterns and daily decision making to best understand how patient thinks through each challenge. TIRs are now the standard

Summary Downloading remains as important as ever-no excuses for clinicians not to look at the data with the patient We are doing better with standardization of glucometrics Always observe concordance of HbA1c Real-time and retrospective review of CGM is helpful for many and many if not most patients will require assistance from you Our first HCL is an amazing tool for many but like all technologies has pros and cons and is not for everyone.